Guido Ficarra

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

Maria Vittoria Dieci, Carmen Criscitiello, Aïcha Goubar et al. · Annals of Oncology · 2014 · 465 citations · Full text

Medicine, Immunology, Oncology +17

Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis

Maria Vittoria Dieci, Elena Barbieri, Federico Piacentini et al. · Annals of Oncology · 2012 · 198 citations · Full text

Medicine, Oncology, Breast Oncology +15

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

Maria Vittoria Dieci, Aleix Prat, Enrico Tagliafico et al. · Annals of Oncology · 2016 · 158 citations · Full text

Medicine, Immunology, Oncology +17

Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management

Valentina Guarneri, Simona Giovannelli, Guido Ficarra et al. · The Oncologist · 2008 · 153 citations · Full text

Medicine, Oncology, Breast Oncology +16

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients

Valentina Guarneri, Maria Vittoria Dieci, Elena Barbieri et al. · Annals of Oncology · 2013 · 142 citations · Full text

Medicine, Cancer Biology, Oncology +16